Optimal dose of Cropidogrel to prevent stent thrombosis after drug-eluting stent implantation in Japanese : a randomised control trial

Optimal dose of Cropidogrel to prevent stent thrombosis after drug-eluting stent implantation in Japanese : a randomised control trial - Optimal dose of Cropidogrel to prevent stent thrombosis after drug-eluting stent implantation in Japanese : a randomised control trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005240

Enrollment

200

Registered

2011-03-11

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

100 patients who underwent coronary intervention and deployed drug-eluting stent at Chiba university hospital since November 2007 are randomly assigned to clopidogrel 75mg/day group. After at least 12

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent drug-eluting stent implantation and not meet the exclusion criteria

Exclusion criteria

Exclusion criteria: 1 Acute Myocardial Infarction and coronary disease associate with thrombosis 2 complicated active bleeding , diathesis of thrombosis 3 neutropenia 4 thrombocytepenia 5 sever liver dysfunction 6 chronic renal failure 7 sever uncontroled hypertension 8 allergy for clopidgrel and/or aspirin 9 shock stete sta 10 chronic cardiad failure 11 body weight<40 kg 12 pregnancy 13 comorbid malignancy tumor 14 age > 80 15 poor expectation for prognosis by any cause

Design outcomes

Primary

Measure	Time frame
MACE (major adverse cardiac event), side effect of clopidogrel, bleedin event	—

Countries

Japan

Contacts

Public ContactKenji Ohkubo

Department of Cardiovascular Science and Medicine Chiba University Graduate School of Medicine Department of Cardiovascular Science and Medicine

kenji_ookubo@yahoo.co.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026